Climb Bio Inc (CLYM)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$10.19-3.32%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Climb Bio Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.214
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-0.794
Annual ending 2027-12-31
Revenue	—	763,636
EPS	—	-0.967

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance CLYM116 development with positive safety and modeling data	Climb Bio is advancing CLYM116, an anti-APRIL antibody with promising Phase 1 safety data.	Improving	any major safety issues or trial halts reported	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage and reduce operating losses from recent levels	The company is focused on managing operating losses, which were $15.2M in Q1 2026, improving from prior quarters.	Intact	operating losses increase above $15M per quarter persistently	Operating income: $-15.359M FY2026-Q2; GAAP. Published target: operating loss improves or stays below $15M per quarter next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-15,359,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 833d4ef7-d6a1-4894-8435-574722dbbd65. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Positive clinical and modeling news on pipeline drugs	A supporting condition in Climb Bio Inc's published investment case. The stated target is at least one positive clinical or modeling update per quarter.	Improving	no positive updates or multiple negative news events in 4 quarters	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.97

$-1.05 → $-0.97 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.05	$888,890	10 / 11
2026-07-25	$-1.05	$888,890	10 / 11
2026-07-26	$-1.05	$888,890	10 / 11
2026-07-27	$-1.05	$888,890	10 / 11
2026-07-28	$-1.12	$0	9 / 14
2026-07-29	$-1.12	$0	9 / 14
2026-07-30	$-1.05	$888,890	10 / 11
2026-07-31	$-1.05	$888,890	10 / 11
2026-08-01	$-1.05	$888,890	10 / 11
2026-08-02	$-1.13	$0	8 / 13
2026-08-03	$-1.05	$888,890	10 / 11
2026-08-04	$-1.05	$888,890	10 / 11
2026-08-05	$-1.05	$888,890	10 / 11
2026-08-06	$-1.09	$0	9 / 13
2026-08-07	$-1.03	$750,000	10 / 11
2026-08-08	$-1.12	$0	9 / 12
2026-08-09	$-1.12	$0	9 / 12
2026-08-10	$-1.03	$750,000	10 / 11
2026-08-11	$-1.03	$750,000	10 / 11
2026-08-12	$-1.06	$937,500	9 / 8
2026-08-13	$-1.03	$750,000	10 / 11
2026-08-14	$-1.03	$750,000	10 / 11
2026-08-15	$-1.03	$750,000	10 / 14
2026-08-16	$-1.03	$750,000	10 / 14
2026-08-17	$-1.03	$750,000	10 / 14
2026-08-18	$-1.03	$750,000	10 / 14
2026-08-19	$-1.03	$750,000	10 / 14
2026-08-20	$-1.00	$833,333	10 / 14
2026-08-21	$-1.00	$833,333	10 / 14
2026-08-22	$-1.00	$833,333	10 / 14
2026-08-23	$-1.00	$833,333	10 / 14
2026-08-24	$-1.00	$833,333	10 / 14
2026-08-25	$-1.00	$833,333	10 / 14
2026-08-26	$-1.00	$833,333	10 / 14
2026-08-27	$-1.00	$833,333	10 / 14
2026-08-28	$-1.00	$833,333	10 / 14
2026-08-29	$-1.00	$833,333	10 / 14
2026-08-30	$-1.00	$833,333	10 / 14
2026-08-31	$-1.00	$833,333	10 / 14
2026-09-01	$-1.00	$833,333	10 / 14
2026-09-02	$-1.00	$833,333	10 / 14
2026-09-03	$-1.00	$833,333	11 / 14
2026-09-04	$-0.98	$750,000	11 / 14
2026-09-05	$-0.98	$750,000	11 / 15
2026-09-06	$-0.98	$750,000	11 / 15
2026-09-07	$-0.98	$750,000	11 / 15
2026-09-08	$-0.98	$750,000	11 / 15
2026-09-09	$-0.98	$750,000	11 / 15
2026-09-10	$-0.98	$750,000	11 / 15
2026-09-11	$-0.98	$750,000	11 / 15
2026-09-12	$-0.98	$750,000	11 / 15
2026-09-13	$-0.98	$750,000	11 / 15
2026-09-14	$-0.98	$750,000	11 / 15
2026-09-15	$-0.98	$750,000	11 / 15
2026-09-16	$-0.98	$750,000	11 / 15
2026-09-17	$-0.98	$750,000	11 / 15
2026-09-18	$-0.98	$750,000	11 / 15
2026-09-19	$-0.98	$750,000	11 / 15
2026-09-20	$-0.98	$750,000	11 / 15
2026-09-21	$-0.98	$750,000	11 / 15
2026-09-22	$-0.98	$750,000	11 / 15
2026-09-23	$-0.98	$750,000	11 / 15
2026-09-24	$-0.98	$750,000	11 / 15
2026-09-25	$-0.98	$750,000	11 / 15
2026-09-26	$-0.98	$750,000	11 / 15
2026-09-27	$-0.98	$750,000	11 / 15
2026-09-28	$-0.98	$750,000	11 / 15
2026-09-29	$-0.98	$750,000	11 / 15
2026-09-30	$-0.98	$750,000	11 / 15
2026-10-01	$-0.98	$750,000	11 / 15
2026-10-02	$-0.98	$750,000	11 / 15
2026-10-03	$-1.00	$750,000	11 / 15
2026-10-04	$-1.00	$750,000	11 / 15
2026-10-05	$-1.00	$750,000	11 / 15
2026-10-06	$-0.98	$750,000	11 / 15
2026-10-07	$-0.98	$750,000	11 / 15
2026-10-08	$-0.98	$750,000	11 / 15
2026-10-09	$-0.98	$750,000	11 / 15
2026-10-10	$-0.98	$750,000	11 / 15
2026-10-11	$-0.98	$750,000	11 / 15
2026-10-12	$-0.98	$750,000	11 / 15
2026-10-13	$-0.98	$750,000	11 / 15
2026-10-14	$-0.98	$750,000	11 / 15
2026-10-15	$-0.98	$750,000	11 / 15
2026-10-16	$-0.98	$750,000	11 / 15
2026-10-17	$-0.98	$750,000	11 / 15
2026-10-18	$-0.98	$750,000	11 / 15
2026-10-19	$-0.98	$750,000	11 / 15
2026-10-20	$-0.98	$750,000	11 / 15
2026-10-21	$-0.98	$750,000	11 / 15
2026-10-22	$-0.97	$763,636	11 / 15
2026-10-23	$-0.97	$763,636	11 / 15
2026-10-24	$-0.97	$763,636	11 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	14	0	0
2026-06-01	15	0	0
2026-07-01	15	0	0
2026-08-01	15	0	0
2026-09-01	15	0	0
2026-10-01	16	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 16 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Deutsche BankOct 20

$28.00New observation · no comparable prior

Raymond JamesOct 5

$34.00New observation · no comparable prior

$0$18.70$37.40

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance CLYM116 development with positive safety and modeling dataDirect metric needs a verified mapping
Manage and reduce operating losses from recent levelsOperating income: $-15.359M
Positive clinical and modeling news on pipeline drugsDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-45.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Climb Bio Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CLYM is a speculative clinical-stage biotechnology company, with its prospects tied to drug development rather than established earnings. The thesis is on watch: management is advancing two programs and has extended its cash runway, but evidence is limited and confidence in the assessment is low.

What's priced into Climb Bio Inc

The snapshot provides no valuation comparison or clear account of what market expectations assume, so whether the shares look cheap, fair, or expensive versus peers is unclear. No fragility signals were flagged, but that does not resolve the uncertainty around expectations or the company's loss-making status.

What the fundamentals likely do

Near term, results face elevated risk: the snapshot notes a high-miss-rate industry, recent peer misses, and performance below CLYM’s industry cohort. Over the multi-year view, clinical progress and cash support are the main fundamental supports: cash was $239.2 million in 2026-Q2 after a private placement, and management expects it to fund operations into the second half of 2028. Budoprutug trials are advancing, while initial CLYM116 data showed a roughly 29-day half-life and strong APRIL suppression, but both programs still depend on future clinical evidence.

What Climb Bio Inc hinges on

A guidance cut at the next call would be a meaningful negative, and continued weakening in jobs data could add pressure to cyclical healthcare names. The favorable scenario is continued strong results and higher guidance from sector bellwethers, which could support sector momentum. For CLYM’s multi-year view, upcoming budoprutug data anticipated in Q4 2026 and initial NAVIGATE-2 data expected in H1 2027 are key tests of execution.